After reporting earnings below estimates, Healthcare juggernaut Johnson & Johnson announces a massive $10B Buyback Plan.
This attempt to quell investor concerns does not appear to have done much—shares are lower in pre-market trade.
Buybacks aren’t what they used to be.
If you enjoy the content at iBankCoin, please follow us on Twitter